Jackson Creek Investment Advisors LLC Takes $991,000 Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Jackson Creek Investment Advisors LLC purchased a new stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 30,683 shares of the company’s stock, valued at approximately $991,000. Jackson Creek Investment Advisors LLC owned about 0.05% of Harmony Biosciences as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. China Universal Asset Management Co. Ltd. lifted its position in Harmony Biosciences by 95.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,533 shares of the company’s stock valued at $50,000 after buying an additional 748 shares during the last quarter. Oakworth Capital Inc. acquired a new stake in shares of Harmony Biosciences in the third quarter valued at $150,000. ELCO Management Co. LLC purchased a new stake in shares of Harmony Biosciences in the 3rd quarter valued at $210,000. Livforsakringsbolaget Skandia Omsesidigt purchased a new position in Harmony Biosciences during the 4th quarter valued at about $210,000. Finally, Raymond James & Associates acquired a new position in Harmony Biosciences in the 3rd quarter valued at about $216,000. 86.23% of the stock is currently owned by hedge funds and other institutional investors.

Harmony Biosciences Stock Up 5.7 %

Harmony Biosciences stock traded up $1.66 during mid-day trading on Tuesday, hitting $30.91. The company had a trading volume of 1,739,400 shares, compared to its average volume of 392,055. The company has a quick ratio of 2.72, a current ratio of 2.75 and a debt-to-equity ratio of 0.38. The business has a fifty day moving average of $31.28 and a 200 day moving average of $29.94. The stock has a market cap of $1.76 billion, a price-to-earnings ratio of 15.80, a PEG ratio of 0.41 and a beta of 0.73. Harmony Biosciences Holdings, Inc. has a 1 year low of $18.61 and a 1 year high of $39.26.

Harmony Biosciences (NASDAQ:HRMY) last announced its quarterly earnings results on Thursday, February 22nd. The company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.29). The company had revenue of $168.40 million during the quarter, compared to analysts’ expectations of $168.90 million. Harmony Biosciences had a net margin of 22.16% and a return on equity of 27.49%. Harmony Biosciences’s revenue was up 31.3% on a year-over-year basis. During the same period last year, the firm earned $1.01 earnings per share. On average, sell-side analysts expect that Harmony Biosciences Holdings, Inc. will post 3 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on HRMY shares. Cantor Fitzgerald reissued an “overweight” rating and set a $49.00 price target on shares of Harmony Biosciences in a research report on Friday, April 12th. Bank of America reissued an “underperform” rating and issued a $30.00 price target on shares of Harmony Biosciences in a research report on Tuesday, January 2nd. The Goldman Sachs Group upped their price objective on Harmony Biosciences from $25.00 to $28.00 and gave the stock a “sell” rating in a research report on Tuesday, January 9th. Mizuho decreased their target price on Harmony Biosciences from $42.00 to $40.00 and set a “buy” rating for the company in a report on Tuesday, February 27th. Finally, Needham & Company LLC restated a “buy” rating and set a $50.00 price target on shares of Harmony Biosciences in a report on Tuesday. Two equities research analysts have rated the stock with a sell rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, Harmony Biosciences currently has an average rating of “Moderate Buy” and an average target price of $40.63.

Insider Activity at Harmony Biosciences

In other Harmony Biosciences news, insider Jeffrey Dierks sold 11,979 shares of Harmony Biosciences stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $32.00, for a total transaction of $383,328.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 30.80% of the company’s stock.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.